Free Trial
NASDAQ:RANI

Rani Therapeutics Q2 2026 Earnings Results & Report

Rani Therapeutics logo
$0.53 +0.00 (+0.21%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.58%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.04 versus the -$0.05 consensus estimate, while revenue of $1.71 million topped the $925 thousand estimate by $783.00 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Rani Therapeutics EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Rani Therapeutics Revenue Results

Actual Revenue
$1.71 million
Expected Revenue
$925 thousand
Beat/Miss
Beat by +$783.00 thousand
YoY Revenue Growth
N/A

Rani Therapeutics Q2 2026 Earnings FAQ

Rani Therapeutics (NASDAQ:RANI) reported earnings of -$0.04 per share for Q2 2026, beating the consensus estimate of -$0.05. The report was announced on Thursday, August 13, 2026.

Rani Therapeutics reported revenue of $1.71 million for Q2 2026, against a consensus estimate of $925 thousand.

Rani Therapeutics Earnings Headlines

Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
Rani Therapeutics (RANI) Expected to Release Earnings on Thursday
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections.

Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines. Rani’s work focuses on addressing challenges that have traditionally made many biologic drugs difficult to administer by mouth.

View Rani Therapeutics Profile